Leveraging Clinical Credibility to Drive Towards Category Leadership
TissueTech, Inc., parent company of Amniox Medical, Inc., has a new leader at its helm. Ted Davis is taking over as CEO from the company's founder Amy Tseng. TissueTech is differentiated by its proprietary CRYOTEK tissue-processing developed by CSO Dr. Scheffer Tseng MD, PhD. CRYOTEK preserves the innate biological and structural integrity of the natural placental tissue amniotic product.
Ted Davis knows strategy
Recognizable around the foot and ankle market as one of the early drivers of Wright Medical, Ted's vision is to "transition from our early entrepreneurial phase as a tissue company into the next phase of growth and execution of our clinical programs to successfully secure biologics approvals from FDA, thus becoming a true biotechnology company, built on the technology and base tissue business of today." Working through a Biologics License Application Process (BLA pathway) is not for the faint of heart, but represents a transformational opportunity to build out a premier biologics company based on the unique amniotic platform of Tissue-Tech.
Amniotic opportunity is big
The global amniotic products market is projected to reach USD $ 1.0 billion by 2026 from USD 0.7 billion in 2021. Using an investigational new drug (IND) pathway with the FDA that is reserved for experimental drugs showing great promise, TissueTech has two IND trials underway; wound healing and knee arthritis.
